A Food and Drug Administration advisory committee voted 11-0 against the approval of a Novartis AG drug for acute heart failure, but the company said it plans to persist in developing the drug.. Novartis said it had presented its best evidence gathered thus far, but it plans to continue with the drug serelaxin because of the "urgent patient need." Drugs for acute heart failure have generally been very disappointing.. The...
  